Market Place
Sourcing Support
AMO Outlines AMO-02 Myotonic Dystrophy Development Post-FDA Meet
02 May 2024 //
PR NEWSWIRE
AMO Pharma Announces Collaboration with Population Health Research Institute
15 Feb 2024 //
PR NEWSWIRE
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in CMD1
22 Dec 2021 //
PRNEWSWIRE
AMO Pharma Announces First Patient Enrolled In REACH-CDM
30 Sep 2021 //
PRNEWSWIRE
AMO Pharma Reports +ve Data from Investigator-Led TIDE Study of AMO-02 in ASD
29 Oct 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.